Andras A. Heczey, MD

Location

  • Texas Medical Center

Specialty

Cancer

Phone: 832-822-4242
Fax: 832-825-1453

Contact Information

1102 Bates Street
Suite 1230.06
Houston, TX 77030
United States
Texas

Director, Liver Tumor Program
Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine

Education

School Education Degree Year
Baylor College of Medicine fellowship Pediatric Hematology Oncology 2012
Children's Hospital of Los Angeles residency Pediatrics 2009
Semmelweis Medical University, Hungary residency Infectious Disease 2006
Semmelweis University medical school Doctor of Medicine 2002

About

Dr. Andras Heczey is a physician-scientist and full-time faculty in the Department of Pediatrics of Baylor College of Medicine, Section of Pediatric Hematology and Oncology. He is a member of the multidisciplinary solid tumor team and the Center for Cell and Gene Therapy (CAGT).

Organization

Organization Name Role
American Society of Clinical Oncology (ASCO) Member
American Society of Pediatric Hematology and Oncology (ASPHO) Member
Children's Oncology Group (COG) Member

Research Statement

His research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack cancer cells.

Dr. Heczey has studied and published the first adoptive immunotherapy approach utilizing Natural Killer T cells genetically modified to attack neuroblastoma, he is working on moving this approach from bench-to-bedside in a form of a Phase 1/2a clinical trial.

As the Director of the Liver Tumor Center, Dr. Heczey has developed a strategy to target hepatoblastoma and hepatocellular carcinoma with genetically engineered T lymphocytes and he is currently optimizing this strategy for a smooth transition into the clinic.

Dr. Heczey’s research is focused on redirecting the immune system to attack and kill cancer cells by using genetically engineered T cells and Natural Killer T cells. He has developed bispecific T cell engagers and chimeric antigen receptors, which when expressed in T cells, specifically target hepatoblastoma and hepatocellular carcinoma. His goal is to cure all patients with liver cancers by translating these methods from the laboratory setting to the patient care clinic.

Selected Publications